Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of ($1.07), $0.37 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $416 thousand.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.